Earnings
| ShowHide Related Items >><< - 06/21/22
- Arcellx names Maryam Abdul-Kareem as General Counsel
- 05/26/22
- Kinnate Biopharma to present trial design candidate KIN-3248 data at ASCO
- 05/19/22
- Kinnate Biopharma treatment of stage IIb-IV melanoma granted orphan designation
- 04/18/22
- Kinnate Biopharma announces first patient dosed in Phase 1 trial of KIN-3248
- 07/28/22 H.C. Wainwright
- Kinnate Biopharma initiated with a Buy at H.C. Wainwright
- 06/03/22 Wedbush
- Wedbush downgrades Turning Point, says deal positive for small/mid-cap biotechs
- 05/18/22 Piper Sandler
- Kinnate Biopharma price target lowered to $30 from $52 at Piper Sandler
- 01/07/22 Wedbush
- Kinnate Biopharma price target lowered to $44 from $53 at Wedbush
- 05/12/22
- Kinnate Biopharma reports Q1 EPS (61c), consensus (61c)
- 03/28/22
- Kinnate Biopharma reports FY EPS ($2.06), consensus (59c)
|
Syndicate
| ShowHide Related Items >><< - 06/22/22
- Silence Therapeutics PLC (ADS) trading resumes
- 06/22/22
- Silence Therapeutics PLC (ADS) trading halted, volatility trading pause
- 05/16/22
- Silence Therapeutics PLC (ADS) trading resumes
- 05/16/22
- Silence Therapeutics PLC (ADS) trading halted, volatility trading pause
- 03/31/22 Chardan
- Silence Therapeutics initiated with a Buy at Chardan
- 03/22/22 H.C. Wainwright
- Silence Therapeutics price target lowered to $95 from $100 at H.C. Wainwright
|
Hot Stocks
| ShowHide Related Items >><< - 08/05/22
- T-Mobile announces 'first-ever full investment grade rating'
- 08/05/22
- S&P raises issuer credit rating on T-Mobile to 'BBB-' from 'BB+'
- 07/25/22
- Paladin Cloud receives investment from T-Mobile Ventures
- 07/13/22
- T-Mobile, Deutsche Telekom announces Spoke to use T IoT for safer cycling
- 07/28/22 Cowen
- T-Mobile price target raised to $187 from $179 at Cowen
- 07/28/22 Barclays
- T-Mobile price target raised to $160 from $150 at Barclays
- 07/28/22 Scotiabank
- T-Mobile upgraded to Outperform at Scotiabank on outgrowth over peers
- 07/28/22 Scotiabank
- T-Mobile upgraded to Outperform from Sector Perform at Scotiabank
- 07/27/22
- T-Mobile raises FY22 core adjusted EBITDA view to $26B-$26.3B from $25.8B-$26.2B
- 07/27/22
- T-Mobile reports Q2 EPS (9c), consensus 28c
- 07/26/22
- Notable companies reporting before tomorrow's open
- 07/26/22
- Notable companies reporting before tomorrow's open
|
Hot Stocks
|
Algonquin Power has… Algonquin Power has approved and declared the following common and preferred share dividends: 18.08c per common share, payable on October 14 to shareholders of record on September 29 for the period from July 1 to September 30; shareholders receiving dividends in cash can elect to receive the dividend in Canadian dollars in the amount of C$0.2312. C$0.32263 per preferred share, Series A, payable in cash on October 3 to preferred share, Series A holders of record on September 15 for the period from June 30 to, but excluding, September 30. C$0.31819 per preferred share, Series D, payable in cash on October 3 to preferred share, Series D holders of record on September 15 for the period from June 30 to, but excluding, September 30. . Plan Shares will be acquired by way of a treasury purchase at the average market price as defined in the Plan less a 3% discount. ShowHide Related Items >><< - 05/12/22
- Algonquin Power increases common dividend 6% to $0.1808 per share
- 05/04/22 National Bank
- Algonquin Power downgraded on rising bond yields at National Bank
- 05/04/22 National Bank
- Algonquin Power downgraded to Sector Perform from Outperform at National Bank
- 11/10/21 BMO Capital
- Algonquin Power upgraded to Outperform from Market Perform at BMO Capital
- 05/12/22
- Algonquin Power reports Q1 adjusted EPS 21c, consensus 20c
|
On The Fly
|
Check out this evening's… ShowHide Related Items >><< - 16:46 Today
- Toast up 9% to $19.80 after smaller than expected Q2 loss, raised guidance
- 07/26/22
- Cathie Wood's ARK Investment bought 113K shares of Toast today
- 07/07/22
- Toast acquires employee scheduling, communication solution Sling, no terms
- 05/13/22
- Toast rises 15.2%
- 06/07/22
- System1 set to join Russell 2000, Russell 3000 Indexes
- 05/13/22
- Starboard takes stake in Humana, exits System1
- 04/19/22
- System1 falls -33.8%
- 04/19/22
- System1 falls -28.6%
- 05/04/22
- Smith Micro names Von Cameron as Chief Revenue Officer
- 16:22 Today
- SmartRent falls 28% to $4.02 after Q2 earnings miss and guidance cut
- 05/17/22
- SmartRent director buys $1.04M in common stock
- 04/28/22
- SmartRent names Hiroshi Okamoto CFO
- 03/24/22
- SmartRent acquires SightPlan for about $135M in all-cash transaction
- 17:27 Today
- Rivian Automotive cuts FY22 adjusted EBITDA target to loss of $5.45B from $4.75B
- 16:18 Today
- Rivian Auto says supply chain constraints 'to remain limiting factor' in output
- 16:17 Today
- Rivian Automotive reports Q2 output of 4.40K and deliveries of 4.47K vehicles
- 16:15 Today
- Rivian Automotive affirms 2022 production target of 25K vehicles
- 18:19 Today
- Quanterix director buys $100K in common stock
- 08/10/22
- Quanterix director Walt acquires 150,000 common shares
- 08/10/22
- Quanterix chairman Madaus buys nearly 90,000 common shares
- 08/08/22
- Quanterix executive chairman Krusovsky resigns
- 08/04/22
- Poshmark offers new styles, marketing for back to school season
- 06/09/22
- Poshmark director sells $1.0M in common stock
- 06/09/22
- Poshmark set to join Russell 3000 Index
- 05/22/22
- Fly Intel: Top five weekend stock stories
- 16:05 Today
- Pear Therapeutics reduced workforce on July 25 due to macro environment
- 08/10/22
- Pear Therapeutics announces publication of insomnia analysis
- 08/08/22
- Pear Therapeutics, SelectHealth announce reSET-O added as covered benefit
- 08/03/22
- Pear, Cove Behavioral avail patients PDT reSET-O for opiod abuse treatment
PCT PureCycle Technologies - 17:31 Today
- PureCycle Technologies provides Q2 operational update
- 06/30/22
- PureCycle CEO Mike Otworth to resign, Dustin Olson promoted to CEO
- 05/12/22
- PureCycle Technologies reports liquidity of $609.9M
- 05/12/22
- PureCycle reports 215M pounds of polypropylene under LOI
- 06/07/22
- Payoneer Global, Fiserv collaborate to streamline cross-border payments
- 06/01/22
- Shoplazza to bring Payoneer Checkout to its 360,000+ merchants
- 06/01/22
- Payoneer Global and Optty partner for Buy Now Pay Later platform
- 05/25/22
- Payoneer Global appoints Caplan co-CEO alongside current CEO Scott Galit
- 05/10/22
- Olo appoints Diego Panama as chief revenue officer
- 04/14/22
- Olo, SOCi partner for SOCi integration with Olo API
- 03/04/22
- Olo announces integration with Radar
- 02/23/22
- Olo launches Olo Pay
- 08/03/22
- Mister Car Wash acquires Top Wash in Minnesota
- 06/27/22
- Mister Car Wash falls -5.3%
- 04/29/22
- Mister Car Wash acquires Speedwash, terms undisclosed
- 03/24/22
- Mister Car Wash jumps over 3% to $16.39 after Q4 earnings beat
- 03/11/22
- LegalZoom trading resumes
- 03/11/22
- LegalZoom trading halted, volatility trading pause
- 03/10/22
- LegalZoom board approves $150M share repurchase program
- 03/10/22
- LegalZoom appoints Block CLO Sivan Whiteley to board of directors
- 06/06/22
- DISCO appoints Tom Furr as CMO
- 06/01/22
- CS Disco falls -10.8%
- 04/28/22
- DISCO appoints Jignasha Amin Grooms as CHRO
- 08/10/22
- Joby Aviation expands contract with U.S. Air Force's Agility Prime program
- 05/26/22
- Joby Aviation receives Part 135 Air Carrier Certificate from FAA
- 05/10/22
- Joby Aviation says pre-production aircraft demonstrates low noise profile
- 04/18/22
- Joby Aviation rises 4.8%
- 16:26 Today
- Illumina cuts FY22 core Illumina revenue growth view to 3.5%-4.5%
- 16:22 Today
- Illumina drops 22% to $177 after Q2 results miss estimates, FY22 guidance cut
- 06/09/22
- Illumina drops 6% to $210.00 after departure of CFO
- 06/09/22
- Illumina CFO Sam Samad to depart, Joydeep Goswami named interim CFO
- 16:12 Today
- ForgeRock reports Q2 ARR $201.6M, up 30% y/y
- 05/11/22
- ForgeRock introduces ForgeRock Autonomous Access
- 03/02/22
- ForgeRock falls -10.0%
- 05/12/22
- Expensify authorizes up to $50M share buyback program
CSSE Chicken Soup for the Soul - 16:04 Today
- Chicken Soup for the Soul reports Q2 adjusted EBITDA $5.6M vs. $3.2M y/y
- 08/10/22
- Nasdaq says Redbox trading to be halted following after-hours session on Aug. 10
- 08/09/22
- Redbox's stockholders approve merger proposal with Chicken Soup for the Soul
- 07/14/22
- Crackle, Popcornflix FAST channels launch on FuboTV
- 07/26/22
- Co-Diagnostics to expand OEM agreement with Bio Molecular Systems
- 07/11/22
- Co-Diagnostics announces shipment of monkeypox virus test
- 07/11/22
- Co-Diagnostics announces shipment of monkeypox virus test
- 05/26/22
- Co-Diagnostics completes principal design of test for monkeypox virus
- 08/05/22
- Certara announces release 5.2.0 of Pinnacle 21 Enterprise
- 07/28/22
- Certara enters collaboration with Memorial Sloan Kettering Cancer Center
- 07/25/22
- Certara appoints Crane as new independent board member
- 07/13/22
- Certara appoints Eran Broshy to board of directors
- 07/25/22
- Biolase receives five new United States patents, seven new foreign patents
- 07/13/22
- Biolase announces pilot program with Einstein Healthcare Network's residency
- 07/07/22
- Biolase promotes Jennifer Bright to CFO, Steven Sandor to COO
- 07/05/22
- Biolase announces partnership with TeamSmile
- 07/14/22 Goldman Sachs
- Payoneer Global upgraded to Buy from Neutral at Goldman Sachs
- 05/13/22 Northland
- Payoneer Global price target lowered to $9 from $14 at Northland
- 05/13/22 Citi
- Payoneer Global price target raised to $7.50 from $6.50 at Citi
- 03/04/22 Needham
- Payoneer Global price target lowered to $7 from $13 at Needham
- 05/17/22 Mizuho
- Toast price target lowered to $18 from $19 at Mizuho
- 05/13/22 Needham
- Toast price target lowered to $21 from $38 at Needham
- 05/13/22 Canaccord
- Toast price target lowered to $25 from $34 at Canaccord
- 05/09/22 Mizuho
- Toast price target lowered to $19 from $23 at Mizuho
- 07/28/22 Morgan Stanley
- LegalZoom downgraded to Underweight on estimate risk at Morgan Stanley
- 07/28/22 Morgan Stanley
- LegalZoom downgraded to Underweight from Equal Weight at Morgan Stanley
- 07/14/22 Morgan Stanley
- LegalZoom price target lowered to $12 from $13 at Morgan Stanley
- 04/19/22 Citi
- LegalZoom assumed with Buy from Neutral at Citi
- 07/27/22 Raymond James
- Joby Aviation initiated with a Market Perform at Raymond James
- 04/28/22 JPMorgan
- Joby Aviation initiated with a Neutral at JPMorgan
- 04/11/22 Deutsche Bank
- Joby Aviation initiated with a Hold at Deutsche Bank
- 04/05/22 Cantor Fitzgerald
- Joby Aviation initiated with an Overweight at Cantor Fitzgerald
PCT PureCycle Technologies - 03/10/22 Craig-Hallum
- PureCycle Technologies price target lowered to $18 from $26 at Craig-Hallum
- 03/10/22 Oppenheimer
- PureCycle Technologies price target lowered to $16 from $28 at Oppenheimer
- 11/12/21 Craig-Hallum
- PureCycle Technologies price target lowered to $26 from $48 at Craig-Hallum
- 09/23/21 Cowen
- PureCycle Technologies initiated with an Outperform at Cowen
- 08/09/22 Cowen
- Quanterix downgraded to Market Perform from Outperform at Cowen
- 08/09/22 SVB Securities
- Quanterix downgraded to Market Perform from Outperform at SVB Securities
- 05/11/22 Cowen
- Quanterix price target lowered to $38 from $60 at Cowen
- 03/15/22 BTIG
- Quanterix price target lowered to $60 from $92 at BTIG
- 05/16/22 H.C. Wainwright
- Co-Diagnostics price target lowered to $12 from $15 at H.C. Wainwright
- 12/29/21 Sidoti
- Sidoti starts Co-Diagnostics at Buy, sees opportunities opened by COVID-19 test
- 12/29/21 Sidoti
- Co-Diagnostics initiated with a Buy at Sidoti
- 07/18/22 Piper Sandler
- Olo price target lowered to $13 from $14 at Piper Sandler
- 06/17/22 JPMorgan
- Olo price target lowered to $21 from $26 at JPMorgan
- 02/24/22 Truist
- Olo price target lowered to $25 from $45 at Truist
- 02/24/22 Piper Sandler
- Olo price target lowered to $20 from $33 at Piper Sandler
- 05/23/22 Jefferies
- CS Disco price target lowered to $35 from $40 at Jefferies
- 05/13/22 Needham
- CS Disco price target lowered to $35 from $50 at Needham
- 05/13/22 Cowen
- CS Disco price target lowered to $35 from $45 at Cowen
- 05/13/22 Canaccord
- CS Disco price target lowered to $35 from $45 at Canaccord
- 03/11/22 Lake Street
- Smith Micro price target lowered to $6 from $9 at Lake Street
- 03/11/22 B. Riley
- Smith Micro price target lowered to $6.25 from $9.50 at B. Riley
- 03/11/22 Dawson James
- Smith Micro price target lowered to $8.30 from $11.40 at Dawson James
- 01/03/22 B. Riley
- iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
- 06:21 Today Loop Capital
- Expensify upgraded to Buy from Hold at Loop Capital
- 07/18/22 BofA
- BofA upgrades 'category disruptor' Expensify to Buy with $25 target
- 07/18/22 BofA
- Expensify upgraded to Buy from Neutral at BofA
- 06/15/22 JPMorgan
- Expensify price target lowered to $30 from $47 at JPMorgan
- 16:41 Today Piper Sandler
- Illumina miss 'surprising' given backlog, says Piper Sandler
- 07/14/22 Canaccord
- Illumina merger challenge not reflection of merits, says Canaccord
- 07/13/22 Piper Sandler
- Illumina uncertainty over Grail continues with ruling, says Piper Sandler
- 07/13/22 Barclays
- Illumina downgraded to Underweight from Equal Weight at Barclays
- 07/11/22 BofA
- BofA starts System1 at Buy with $12 price target
- 07/11/22 BofA
- System1 initiated with a Buy at BofA
- 04/26/22 Evercore ISI
- System1 initiated with an In Line at Evercore ISI
- 04/06/22 DA Davidson
- System1 price target raised to $26 from $23 at DA Davidson
- 07/13/22 Piper Sandler
- ForgeRock price target raised to $25 from $24 at Piper Sandler
- 06/22/22 JPMorgan
- ForgeRock price target lowered to $30 from $36 at JPMorgan
- 05/12/22 Deutsche Bank
- ForgeRock price target lowered to $15 from $16 at Deutsche Bank
- 05/12/22 Mizuho
- ForgeRock price target lowered to $24 from $32 at Mizuho
- 06/24/22 BTIG
- Pear Therapeutics price target lowered to $11 from $12 at BTIG
- 05/24/22 Cowen
- Pear Therapeutics revenues raised on strong Rx growth, says Cowen
- 05/17/22 Chardan
- Pear Therapeutics price target lowered to $13 from $16 at Chardan
- 05/17/22 Citi
- Pear Therapeutics price target raised to $11 from $10 at Citi
CSSE Chicken Soup for the Soul - 07/12/22 B. Riley
- Chicken Soup sees positive free cash flow by year-end, says B. Riley
- 06/14/22 DA Davidson
- DA Davidson likes Chicken Soup for the Soul amid strong box office, Redbox deal
- 05/27/22 B. Riley
- Redbox downgraded to Sell from Neutral at B. Riley
- 05/17/22 Guggenheim
- Chicken Soup for the Soul resumed with a Buy at Guggenheim
- 07/22/22 Cantor Fitzgerald
- SmartRent assumed with an Overweight at Cantor Fitzgerald
- 07/19/22 Keefe Bruyette
- Bain Capital sold 5% of stake in SmartRent, says Keefe Bruyette
- 05/25/22 Compass Point
- Compass Point starts SmartRent at Buy, sees 'exponential growth potential'
- 05/25/22 Compass Point
- SmartRent initiated with a Buy at Compass Point
- 07/27/22 MKM Partners
- MKM assumes Poshmark with Neutral rating, cites near-term profitability concerns
- 07/27/22 MKM Partners
- Poshmark assumed with a Neutral at MKM Partners
- 06/29/22 Raymond James
- Poshmark downgraded to Market Perform from Outperform at Raymond James
- 06/28/22 Stifel
- Poshmark price target raised to $13 from $12 at Stifel
- 06/27/22 Goldman Sachs
- Mister Car Wash downgraded to Sell from Neutral at Goldman Sachs
- 05/13/22 BMO Capital
- Mister Car Wash price target lowered to $18 from $23 at BMO Capital
- 05/13/22 Piper Sandler
- Mister Car Wash price target lowered to $13 from $18 at Piper Sandler
- 03/25/22 BMO Capital
- Mister Car Wash price target lowered to $23 from $25 at BMO Capital
- 05/20/22 Lake Street
- Biolase initiated with a Buy at Lake Street
- 08/19/21 Ascendiant
- Biolase price target raised to $3 from $2 at Ascendiant
- 07/18/22 Deutsche Bank
- Rivian Automotive price target lowered to $46 from $69 at Deutsche Bank
- 07/13/22 Canaccord
- Rivian Automotive initiated with a Buy at Canaccord
- 07/08/22 Wedbush
- Wedbush ups Rivian target, says story 'starting to turn the corner'
- 07/06/22 RBC Capital
- Rivian Automotive's Q2 deliveries stronger than expected, says RBC Capital
- 08/10/22 Piper Sandler
- Certara price target lowered to $25 from $28 at Piper Sandler
- 07/15/22 SVB Securities
- Certara initiated with an Outperform at SVB Securities (earlier)
- 07/13/22 Barclays
- Certara price target lowered to $24 from $25 at Barclays
- 07/01/22 Piper Sandler
- Certara initiated with an Overweight at Piper Sandler
- 16:27 Today
- Toast raises FY22 revenue view to $2.62B-$2.66B, consensus $2.54B
- 16:26 Today
- Toast sees Q3 revenue $700M-$730M, consensus $665.08M
- 16:26 Today
- Toast reports Q2 EPS (11c) vs (64c) last year
- 13:54 Today
- Notable companies reporting after market close
- 16:05 Today
- System1 sees FY22 revenue $900M-$930M, consensus $997.34M
- 16:04 Today
- System1 reports Q2 revenue $220M, consensus $218.82M
- 04/04/22
- System1 sees FY22 revenue $1B
- 04/04/22
- System1 reports Q4 revenue $238.9M vs. $160.9M last year
- 16:08 Today
- Smith Micro reports Q2 adjusted EPS (9c) vs (1c) last year
- 05/04/22
- Smith Micro reports Q1 EPS (13c), consensus (8c)
- 03/10/22
- Smith Micro reports Q4 adjusted EPS (4c), consensus (3c)
- 16:22 Today
- SmartRent cuts FY22 revenue view to $155M-$180M from $220M-$250M
- 16:21 Today
- SmartRent sees Q3 revenue $43M-$47M, consensus $75.4M
- 16:20 Today
- SmartRent reports Q2 EPS (13c), consensus (11c)
- 05/11/22
- SmartRent sees FY22 revenue $220M-$250M, consensus $238.1M
- 16:14 Today
- Rivian Automotive reports Q2 EPS ($1.89), consensus ($1.67)
- 07/28/22
- Amazon reports Q2 EPS (20c) with Rivian loss, consensus 13c
- 05/11/22
- Rivian Automotive reports Q1 adjusted EPS ($1.43), consensus ($1.44)
- 08/08/22
- Quanterix reports Q2 revenue $23.5M, consensus $30.1M
- 05/10/22
- Quanterix reports Q1 net loss $18.2M vs.$10.1M loss last year
- 03/01/22
- Quanterix reports Q4 revenue $30.29M, consensus $28.49M
- 16:06 Today
- Poshmark reports Q2 EPS (29c), consensus (27c)
- 05/12/22
- Poshmark sees Q2 revenue $86M-$88M, consensus $89.83M
- 05/12/22
- Poshmark reports Q1 EPS (18c), consensus (22c)
- 05/12/22
- Notable companies reporting after market close
- 16:04 Today
- Pear Therapeutics reports Q2 EPS 4c, consensus (25c)
- 05/16/22
- Pear Therapeutics backs FY22 revenue view $22M, consensus $21.06M
- 05/16/22
- Pear Therapeutics reports Q1 EPS (17c), consensus (24c)
- 03/28/22
- Pear Therapeutics sees FY22 revenue $22M, consensus $21.79M
- 16:27 Today
- Payoneer Global raises FY22 revenue view to $580M-$590M, consensus $563.1M
- 16:26 Today
- Payoneer Global reports Q2 EPS 1c, consensus (6c)
- 05/12/22
- Payoneer Global sees FY22 revenue $550M-$560M, consensus $535.48M
- 05/12/22
- Payoneer Global reports Q1 EPS 6c, consensus (5c)
- 16:30 Today
- Olo cuts FY22 revenue view to $183M-$184M, consensus $195.6M
- 16:29 Today
- Olo sees Q3 revenue $46.5M-$47.0M, consensus $51.1M
- 16:29 Today
- Olo reports Q2 EPS 1c, consensus 0c
- 05/10/22
- Olo sees Q2 revenue $45.5M-$46M, consensus $45.48M
- 16:07 Today
- Mister Car Wash cuts FY22 EPS view to 36c-39c from 44c-47c, consensus 45c
- 16:07 Today
- Mister Car Wash reports Q2 adjusted EPS 11c, consensus 12c
- 05/12/22
- Mister Car Wash backs FY22 EPS view of 44c-47c, consensus 46c
- 05/12/22
- Mister Car Wash reports Q1 EPS 11c, consensus 11c
- 16:16 Today
- LegalZoom cuts FY22 revenue view to $612M-$616M from $650-$660M
- 16:05 Today
- LegalZoom sees Q3 revenue $149M-$151M, consensus $171.21M
- 16:05 Today
- LegalZoom reports Q2 EPS 5c, consensus 2c
- 05/12/22
- LegalZoom sees Q2 revenue $162M-$164M, consensus $165.08M
- 16:10 Today
- CS Disco cuts FY22 revenue view to $132M-$136M from $149M-$153M
- 16:10 Today
- CS Disco sees Q3 revenue $32M-$34M, consensus $38.29M
- 16:09 Today
- CS Disco reports Q2 adjusted (23c), consensus (27c)
- 05/12/22
- CS Disco sees Q2 revenue $32M-$34M, consensus $34.02M
- 16:20 Today
- Joby Aviation reports Q2 EPS (9c), consensus (14c)
- 16:07 Today
- Illumina cuts FY22 adjusted EPS view to $2.75-$2.90 from $4.00-$4.20
- 16:05 Today
- Illumina reports Q2 adjusted EPS 57c, consensus 65c
- 05/05/22
- Illumina sees FY22 adjusted EPS $4.00-$4.20, consensus $4.15
- 16:13 Today
- ForgeRock sees FY22 adjusted EPS (49c)-(44c), consensus (42c)
- 16:12 Today
- ForgeRock sees Q3 adjusted EPS (17c)-(13c), consensus (7c)
- 16:11 Today
- ForgeRock reports Q2 adjusted EPS (17c), consensus (21c)
- 05/11/22
- ForgeRock cuts FY22 EPS view to (45c)-(41c) from (38c)-(34c), consensus (36c)
- 16:02 Today
- Expensify reports Q2 EPS (10c), consensus 9c
- 05/12/22
- Expensify backs long-term revenue growth view of 25%-35%
- 05/12/22
- Expensify reports Q1 EPS (9c), consensus 5c
- 03/30/22
- Expensify sees Q1 revenue $38.6M-$39.6M, consensus $40.34M
CSSE Chicken Soup for the Soul - 16:03 Today
- Chicken Soup for the Soul reports Q2 EPS ($1.39), consensus (72c)
- 05/11/22
- Chicken Soup for the Soul reports Q1 adjusted EPS (83c), consensus (71c)
- 03/31/22
- Chicken Soup for the Soul reports Q4 EPS ($1.38), consensus (51c)
- 16:02 Today
- Co-Diagnostics reports Q2 EPS (8c), consensus 10c
- 05/12/22
- Co-Diagnostics reports Q1 EPS 34c, consensus 17c
- 03/24/22
- Co-Diagnostics sees Q1 EPS 17c-20c, consensus 11c
- 08/09/22
- Certara cuts FY22 EPS view to 43c-48c from 48c-53c, consensus 50c
- 08/09/22
- Certara reports Q2 adjusted EPS 9c, consensus 11c
- 05/05/22
- Certara reiterates FY22 adjusted EPS view 48c-53c, consensus 44c
- 05/05/22
- Certara reports Q1 adjusted EPS 11c, consensus 9c
- 16:18 Today
- Biolase still sees 2022 revenue growth of at least 15%, consensus $43.97M
- 16:18 Today
- Biolase sees Q3 revenue $10.5M, consensus $10.43M
- 16:17 Today
- Biolase reports Q2 EPS (91c), consensus (62c)
- 05/12/22
- Biolase sees Q2 revenue above $10.5M, consensus $10.2M
|
Hot Stocks
|
Agios Pharmaceuticals… Agios Pharmaceuticals announced that data from the core period of the open-label, Phase 2 study of PYRUKYND in adults with non-transfusion-dependent alpha- or beta-thalassemia were published on August 11, 2022, in The Lancet. Data from this study were previously presented at the 2021 European Hematology Association Annual Congress. PYRUKYND is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase enzymes. "Consistent with previously reported findings, the data reported today underscore the potential of PK activation to improve hallmarks of alpha- and beta-thalassemia, including hemolysis and ineffective erythropoiesis," said Kevin Kuo, M.D., hematologist at University of Toronto, Toronto General Hospital, and an investigator in the study. "Thalassemia is a rare, debilitating lifelong blood disorder characterized by severe complications, with no treatment options for those with alpha-thalassemia and limited options for those with beta-thalassemia. These data demonstrate the potential clinical benefits of mitapivat for a broad spectrum of thalassemia patients and support its continued investigation in pivotal trials." ShowHide Related Items >><< AGIO Agios Pharmaceuticals - $25.98 /
-2.2499 (-7.97%) - 07/12/22
- Agios names Brian Goff CEO, Jackie Fouse transition to role of chair of board
- 06/13/22
- Centogene, Agios Pharmaceuticals expand PYRUKYND partnership
- 06/10/22
- Agios Pharmaceuticals presents clinical data on benefits of PYRUKYND
- 05/18/22
- Agios Pharmaceuticals chief scientific officer Bruce Car to resign
AGIO Agios Pharmaceuticals - $25.98 /
-2.2499 (-7.97%) - 07/27/22 SVB Securities
- Agios Pharmaceuticals upgraded to Outperform from Market Perform at SVB Securities
- 02/25/22 RBC Capital
- Agios Pharmaceuticals price target raised to $67 from $61 at RBC Capital
- 02/24/22 H.C. Wainwright
- Agios Pharmaceuticals price target lowered to $96 from $98 at H.C. Wainwright
- 02/18/22 H.C. Wainwright
- Agios Pharmaceuticals price target raised to $98 from $95 at H.C. Wainwright
AGIO Agios Pharmaceuticals - $25.98 /
-2.2499 (-7.97%) - 08/04/22
- Agios Pharmaceuticals reports Q2 EPS ($1.68), consensus ($1.75)
- 05/05/22
- Agios Pharmaceuticals reports Q1 EPS ($1.74), consensus ($1.81)
- 02/24/22
- Agios Pharmaceuticals reports Q4 EPS ($1.74), consensus ($1.69)
|
Hot Stocks
|
Taro Pharmaceuticals has… ShowHide Related Items >><< - $34.70 /
-0.2198 (-0.63%) - 02/22/22
- Taro Pharmaceutical to acquire Alchemee, terms undisclosed
- $34.70 /
-0.2198 (-0.63%) - 01/31/22 H.C. Wainwright
- Taro Pharmaceutical price target lowered to $73 from $75 at H.C. Wainwright
- 01/18/22 H.C. Wainwright
- Taro Pharmaceutical price target lowered to $75 from $82 at H.C. Wainwright
- $34.70 /
-0.2198 (-0.63%) - 05/26/22
- Taro Pharmaceutical reports Q4 EPS 73c vs. (78c) last year
|
Hot Stocks
|
In a regulatory filing,… In a regulatory filing, Quanterix director Sarah Hlavinka disclosed the purchase of 10.1K common shares of the company on August 11 at a price of $9.89 per share. Shares of Quanterix rose 18.7% today following insider buying activity yesterday evening and are up another 6.2% afterhours. ShowHide Related Items >><< - 08/10/22
- Quanterix director Walt acquires 150,000 common shares
- 08/10/22
- Quanterix chairman Madaus buys nearly 90,000 common shares
- 08/08/22
- Quanterix executive chairman Krusovsky resigns
- 04/22/22
- Quanterix granted Breakthrough Device designation by the FDA for Simoa
- 08/09/22 Cowen
- Quanterix downgraded to Market Perform from Outperform at Cowen
- 08/09/22 SVB Securities
- Quanterix downgraded to Market Perform from Outperform at SVB Securities
- 05/11/22 Cowen
- Quanterix price target lowered to $38 from $60 at Cowen
- 03/15/22 BTIG
- Quanterix price target lowered to $60 from $92 at BTIG
- 08/08/22
- Quanterix reports Q2 revenue $23.5M, consensus $30.1M
- 05/10/22
- Quanterix reports Q1 net loss $18.2M vs.$10.1M loss last year
- 03/01/22
- Quanterix reports Q4 revenue $30.29M, consensus $28.49M
- 08/09/22
- What You Missed On Wall Street On Tuesday
- 08/09/22
- What You Missed On Wall Street This Morning
- 08/08/22
- Fly Intel: After-Hours Movers
|
Periodicals
| ShowHide Related Items >><< - 07/27/22
- HSBC Bank USA raises prime rate to 5.5% from 4.75%
- 06/15/22
- HSBC Bank USA raises prime rate to 4.75% from 4%
- 05/02/22
- HSBC to relocate U.S. headquarters to The Spiral
- 04/26/22
- HSBC: Revenue outlook remains 'positive,' sees MSD revenue growth in 2022
- 08/08/22 RBC Capital
- HSBC price target raised to 650 GBp from 590 GBp at RBC Capital
- 08/03/22 Goldman Sachs
- HSBC downgraded to Neutral from Buy at Goldman Sachs
- 08/03/22 Berenberg
- HSBC price target raised to 625 GBp from 560 GBp at Berenberg
- 08/03/22 UBS
- HSBC price target raised to 680 GBp from 635 GBp at UBS
- 04/26/22
- HSBC reports Q1 EPS 14c vs. 19c last year
- 02/23/22
- HSBC reports 2021 EPS 62c vs. 19c last year
- 08/01/22
- HSBC U.K. gives workers GBP1,500 boost in August paychecks, Bloomberg says
- 08/01/22
- American adds HSBC as adviser for potential dual listing, Reuters reports
- 08/01/22
- HSBC rejects Ping An call for split, cites cost, Reuters reports
- 07/21/22
- HSBC unit forms Chinese Communist party committee, FT reports
- 08/01/22
- What You Missed On Wall Street On Monday
- 08/01/22
- What You Missed On Wall Street This Morning
- 04/29/22
- What You Missed On Wall Street On Friday
- 04/29/22
- What You Missed On Wall Street This Morning
- 08/02/22
- HSBC put volume heavy and directionally bearish
- 07/25/22
- HSBC put volume heavy and directionally bearish
- 07/25/22
- Unusually active option classes on open July 25th
- 07/14/22
- HSBC put volume heavy and directionally bearish
|
Hot Stocks
|
Hologic (HOLX) announced… Hologic (HOLX) announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva (NERV) from challenging the validity of the patent rights it assigned to Hologic. "We are pleased that the U.S. Court of Appeals has once again ruled in our favor. This important decision confirms that good faith and fair dealing apply to transactions involving patents and provides greater certainty for companies like Hologic who acquire innovative technologies in order to provide physicians and their patients with the latest solutions," said Essex Mitchell, President of Hologic's GYN Surgical Solutions Division. In 2015, Hologic sued Minerva alleging that the company's endometrial ablation system infringes patents acquired by Hologic through its 2004 purchase of Novacept, the developer of the NovaSure endometrial ablation system for abnormal uterine bleeding. The suit alleged that four years after Hologic's acquisition of Novacept, a former Novacept executive founded Minerva and developed and commercialized an endometrial ablation device using the patented technology that was acquired by Hologic in the Novacept transaction. In 2018, a Delaware district court found Minerva liable for patent infringement and barred the company's invalidity defenses under assignor estoppel. A jury awarded Hologic $4.8M in damages for Minerva's infringement. This decision by the U.S. Court of Appeals is the latest decision in Hologic's favor on this matter. In 2019, the Federal Circuit affirmed the district court ruling on infringement and assignor estoppel. In 2021, the U.S. Supreme Court clarified the scope of assignor estoppel and, on remand, the Federal Circuit again ruled in Hologic's favor, holding that Minerva's invalidity challenge contradicted multiple representations made by the Novacept executive, including in assigning the patent. With the Federal Circuit decision, Minerva must now pay Hologic more than $7M in damages, which includes the $4.8M in damages originally awarded plus post-trial damages and interest. ShowHide Related Items >><< - 04/07/22
- Minerva provides update from Type C Meeting with FDA on roluperidone
- 02/28/22
- Minerva announces publication of Roluperidone Phase 3 study results
- 05/25/22
- Hologic receives CE mark for Panther Fusion EBV Quant Assay
- 05/10/22
- Hologic announces FDA approval of Aptima CMV Quant Assay for Cytomegalovirus
- 07/22/22 Evercore ISI
- Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
- 07/20/22 UBS
- Hologic initiated with a Neutral at UBS
- 07/20/22 BofA
- BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
- 07/20/22 BofA
- Hologic downgraded to Neutral from Buy at BofA
- 03/04/22 H.C. Wainwright
- Minerva price target lowered to $5 from $10 at H.C. Wainwright
- 08/09/22
- Minerva reports Q2 EPS ($1.63), consensus ($1.65)
- 05/04/22
- Minerva reports Q1 EPS (23c), consensus (18c)
- 03/01/22
- Minerva reports Q4 EPS (12c), consensus (19c)
- 07/27/22
- Hologic raises FY22 EPS view to $5.79-$5.84 from $5.45-$5.65
- 07/27/22
- Hologic sees Q4 EPS 60c-65c, consensus 61c
- 07/27/22
- Hologic reports Q3 EPS 95c, consensus 71c
- 07/27/22
- Notable companies reporting after market close
- 04/27/22
- Fly Intel: After-Hours Movers
- 04/04/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|